Publikationen, an denen er mitarbeitet Enrique Raviña Rubira (60)

2017

  1. 3-Oxopyridazin-5-yl-Chalcone Hybrids: Potent Antiplatelet Agents That Prevent Glycoprotein IIb/IIIa Activation

    ChemistrySelect, Vol. 2, Núm. 17, pp. 4920-4933

2014

  1. Synthesis and biological evaluation of a series of aminoalkyl-tetralones and tetralols as dual dopamine/serotonin ligands

    European Journal of Medicinal Chemistry, Vol. 71, pp. 237-249

2011

  1. Potential atypical antipsychotics: Synthesis, binding affinity and SAR of new heterocyclic bioisosteric butyrophenone analogues as multitarget ligands

    MedChemComm, Vol. 2, Núm. 12, pp. 1194-1200

2009

  1. Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif

    Bioorganic and Medicinal Chemistry Letters, Vol. 19, Núm. 21, pp. 6059-6062

  2. Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands

    Bioorganic and Medicinal Chemistry Letters, Vol. 19, Núm. 6, pp. 1773-1778

2008

  1. Synthesis, binding affinity, and molecular docking analysis of new benzofuranone derivatives as potential antipsychotics

    Journal of Medicinal Chemistry, Vol. 51, Núm. 19, pp. 6085-6094

2007

  1. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity

    Journal of Medicinal Chemistry, Vol. 50, Núm. 26, pp. 6476-6484

  2. Multistructure 3D-QSAR studies on a series of conformationally constrained butyrophenones docked into a new homology model of the 5-HT2A receptor

    Journal of Medicinal Chemistry, Vol. 50, Núm. 14, pp. 3242-3255

  3. Synthesis and binding affinity of new pyrazole and isoxazole derivatives as potential atypical antipsychotics

    Bioorganic and Medicinal Chemistry Letters, Vol. 17, Núm. 17, pp. 4873-4877

2006

  1. Efficient consecutive alkylation-Knoevenagel functionalisations in formyl aza-heterocycles using supported organic bases

    Synlett, pp. 3324-3328

  2. Pyridazines part 41: Synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl) pyridazin-3(2H)-ones

    Bioorganic and Medicinal Chemistry Letters, Vol. 16, Núm. 4, pp. 1080-1083

  3. QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine

    Neuropharmacology, Vol. 51, Núm. 2, pp. 251-262

  4. Synthesis and biological evaluation of new quinazoline and cinnoline derivatives as potential atypical antipsychotics

    Chemistry and Biodiversity, Vol. 3, Núm. 1, pp. 106-117

2005

  1. Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics

    Bioorganic and Medicinal Chemistry Letters, Vol. 15, Núm. 12, pp. 3063-3066

2004

  1. Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics

    Bioorganic and Medicinal Chemistry Letters, Vol. 14, Núm. 3, pp. 585-589

  2. Pyridazine derivatives. Part 38: Efficient Heck alkenylation at position 5 of the 6-phenyl-3(2H)-pyridazinone system

    Tetrahedron Letters, Vol. 45, Núm. 17, pp. 3459-3463

  3. Pyridazine derivatives. Part 39: Reactivity of 5-iodopyridazin-3(2H)-ones in palladium-catalysed reactions

    Tetrahedron, Vol. 60, Núm. 52, pp. 12177-12189

  4. Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones

    Bioorganic and Medicinal Chemistry Letters, Vol. 14, Núm. 2, pp. 321-324

2003

  1. Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT2A and 5-HT2C receptor behaviours

    European Journal of Medicinal Chemistry

  2. In vivo and in vitro pharmacological studies of a new hypotensive compound (QF0301B) in rat: Comparison with prazosin, a known α1- adrenoceptor antagonist

    Vascular Pharmacology, Vol. 40, Núm. 2, pp. 97-108